

bluebird bio, Inc.  
Form 3  
June 18, 2013

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Å TVM V LIFE SCIENCE  
 VENTURES GMBH & CO KG  
 (Last) (First) (Middle)

2. Date of Event Requiring Statement  
 (Month/Day/Year)  
 06/18/2013

3. Issuer Name and Ticker or Trading Symbol  
 bluebird bio, Inc. [BLUE]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

C/O TVM CAPITAL  
 GROUP, Å MAXIMILIANSTRASSE  
 35C

(Street)

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
 \_\_\_ Officer \_\_\_ Other  
 (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 \_\_\_ Form filed by One Reporting Person  
 \_\_\_X\_\_\_ Form filed by More than One Reporting Person

MUNICH, Å 2M Å 80539

(City) (State) (Zip)

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Title	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	---	--	---	--

Edgar Filing: bluebird bio, Inc. - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (1) (Instr. 5)	
Series A-1 Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	325,255	\$ <u>(1)</u>	D <u>(5)</u>	Â
Series A-2 Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	624,021	\$ <u>(1)</u>	D <u>(5)</u>	Â
Series B Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	935,783	\$ <u>(1)</u>	D <u>(5)</u>	Â
Series C Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	210,589	\$ <u>(1)</u>	D <u>(5)</u>	Â
Series D Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	158,709	\$ <u>(1)</u>	D <u>(5)</u>	Â
Series A-1 Warrants	Â <u>(2)</u>	11/16/2015	Series A-1 Convertible Preferred Stock <u>(3)</u>	660,982	\$ 12.55	D <u>(5)</u>	Â
Series A-1 Warrants	Â <u>(2)</u>	10/26/2016	Series A-1 Convertible Preferred Stock <u>(3)</u>	440,650	\$ 12.55	D <u>(5)</u>	Â
Series A-1 Warrants	Â <u>(2)</u>	05/03/2017	Series A-1 Convertible Preferred Stock <u>(3)</u>	1,038,674	\$ 12.55	D <u>(5)</u>	Â
Series A-1 Warrants	Â <u>(2)</u>	08/28/2018	Series A-1 Convertible Preferred Stock <u>(3)</u>	236,062	\$ 12.55	D <u>(5)</u>	Â
Series A-1 Warrants	Â <u>(2)</u>	12/18/2018	Series A-1 Convertible Preferred Stock <u>(3)</u>	236,062	\$ 12.55	D <u>(5)</u>	Â
Series A-1 Warrants	Â <u>(2)</u>	04/15/2019	Series A-1 Convertible Preferred Stock <u>(3)</u>	462,681	\$ 12.55	D <u>(5)</u>	Â
Series B Warrants	Â <u>(2)</u>	04/15/2019	Series B Convertible Preferred Stock <u>(4)</u>	287,400	\$ 6.19	D <u>(5)</u>	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TVM V LIFE SCIENCE VENTURES GMBH & CO KG C/O TVM CAPITAL GROUP MAXIMILIANSTRASSE 35C MUNICH, 2 80539	Â	Â X	Â	Â
TVM Capital GmbH C/O TVM CAPITAL GROUP MAXIMILIANSTRASSE 35C MUNICH, 2 80539	Â	Â X	Â	Â
Polack Axel C/O TVM CAPITAL GROUP MAXIMILIANSTRASSE 35C MUNICH, 2 80539	Â	Â X	Â	Â
SCHUHSLER HELMUT C/O TVM CAPITAL GROUP MAXIMILIANSTRASSE 35C MUNICH, 2 80539	Â	Â X	Â	Â
Goll Alexandra C/O TVM CAPITAL GROUP MAXIMILIANSTRASSE 35C MUNICH, 2 80539	Â	Â X	Â	Â
Birner Hubert C/O TVM CAPITAL GROUP MAXIMILIANSTRASSE 35C MUNICH, 2 80539	Â	Â X	Â	Â
Fischer Stefan C/O TVM CAPITAL GROUP MAXIMILIANSTRASSE 35C MUNICH, 2 80539	Â	Â X	Â	Â

## Signatures

/s/Stefan Fischer, Attorney-in-Fact for  
TVM V Life Science Ventures GmbH  
& Co. KG 06/18/2013

\_\_Signature of Reporting Person

Date

/s/Stefan Fischer, Attorney-in-Fact for  
TVM Capital GmbH 06/18/2013

\_\_Signature of Reporting Person

Date

/s/Stefan Fischer, Attorney-in-Fact for  
Axel Polack 06/18/2013

\_\_Signature of Reporting Person

Date

/s/Stefan Fischer, Attorney-in-Fact for Helmut Schuehsler	06/18/2013	
**Signature of Reporting Person		Date
/s/Stefan Fischer, Attorney-in-Fact for Alexandra Goll	06/18/2013	
**Signature of Reporting Person		Date
/s/Stefan Fischer, Attorney-in-Fact for Hubert Birner	06/18/2013	
**Signature of Reporting Person		Date
/s/Stefan Fischer	06/18/2013	
**Signature of Reporting Person		Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares are convertible into bluebird bio, Inc. ("bluebird") Common Stock for the amounts shown and will automatically convert upon the closing of the initial public offering of bluebird without payment of further consideration.
  - (2) This warrant is immediately exercisable.
  - (3) Upon the closing of the initial public offering of bluebird, this warrant to purchase shares of Series A-1 Convertible Preferred Stock will automatically convert on an 18.967-for-one basis into a warrant to purchase shares of Common Stock.
  - (4) Upon the closing of the initial public offering of bluebird, this warrant to purchase shares of Series B Convertible Preferred Stock will automatically convert on an 18.967-for-one basis into a warrant to purchase shares of Common Stock.
- The shares are held directly by TVM V Life Science Ventures GmbH & Co. KG ("TVM V"). TVM V's general partner, TVM Capital GmbH ("TVM"), and its authorized officers, Axel Polack ("Polack"), Helmut Schuehsler ("Schuehsler"), Alexandra Goll ("Goll"), Hubert Birner ("Birner") and Stefan Fischer ("Fischer") may be deemed to share voting and dispositive power over the shares held by TVM V. Each of TVM, Polack, Schuehsler, Goll, Birner and Fischer disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.